|
|
|
|
Science Sparks @ ACTREC
|
 11th March 2024 |
Vol. No. 13 ; Issue No.621 |
|
|
Publications
|
|
1. Dharavath B, Butle A, Chaudhary A, Pal A, Desai S, Chowdhury A, Thorat R, Upadhyay P, Nair S, Dutt A (2024). Recurrent UBE3C-LRP5 translocations in head and neck cancer with therapeutic implications. NPJ Precision Oncology. 8(1): 63.
2. Lokhande M, Kannusamy S, Oak A, Cheulkar S, Chavan S, Mishra V, Gode P, Thakadiyil AS, Mendhe S, Kadam S, Balasubramaniam G, Chaturvedi P, Dikshit R (2024). A hospital-based study of survival in oral cancer patients of Tata Memorial Hospital, Mumbai. Ecancermedicalscience. 18:1669
3. Shivshankar S, Sarade M, Bhojane S, Kolekar S, Patil S, Budukh A. Quality assessment of a rural population-based cancer registry (PBCR) at Ratnagiri, Maharashtra, India for the years 2017-18. Ecancermedicalscience. 18:1672
4. Digholkar G, Varghese R, Pal K, Sharma R (2024). Adipose-derived stem cells: an upcoming novel therapeutic in the management of Erectile dysfunction post radical prostatectomy in prostate cancer patients.International Journal of Impotence Research
5. George K, Chopra S, Rajamanickam K, Joshi K, Swamidas J, Shetty N, Engineer R (2024). Evaluation of liver segmental dose threshold for hepatocyte regeneration following liver stereotactic body radiation therapy. Indian Journal of Medical Research
6. Khanna D, Sharma P, Budukh A, Vishwakarma R, Sharma AN, Bagal S, Tripathi V, Maurya VK, Chaturvedi P, Pradhan S (2024). Rural-urban disparity in cancer burden and care: findings from an Indian cancer registry. BMC Cancer. 24(1):308
7. Gadewal N, Natu A, Sen S, Rauniyar S, Bastikar V, Gupta S (2024).Integrative epigenome-transcriptome analysis unravels cancer-specific over-expressed genes potentially regulating immune microenvironment in clear cell renal cell carcinoma.Biochimica et Biophysica Acta (BBA) - General Subjects
|
|
|
|
|
|
|
Video of the Week
|
|
| Advancing the Understanding and Treatment of Adult and Childhood Cancers with Cancer Biology |
|
| |
|
|
| |
|
|
|
|
Do You Know?
In 2012, Vismodegib (Erivedge) was the first drug approved for basal cell carcinoma, the most common type of skin cance.
|
|
|
|
Cancer News
|
| |
|
Cancer vaccine for dogs almost doubles survival rates in clinical trial.
|
|
New Atlas, 05/03/2024
|
|
The researchers say that their canine cancer vaccine has almost doubled the 12-month survival rate for dogs with some types of cancer. For example, dogs with osteosarcoma have a 35% chance of living for one year after diagnosis when treated with chemotherapy and other conventional treatments...
|
| |
|
First cancer TIL therapy gets FDA approval for advanced melanoma.
|
|
National Cancer Institute, 05/03/2024
|
|
Lifileucel’s approval was based on findings from a clinical trial sponsored by Iovance Biotherapeutics. Among more than 70 participants who were treated with the lifileucel dose ultimately approved by FDA, nearly one-third had at least some reduction in the size of their tumors...
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
2019 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|
